In cannabis, it sometimes feels like every financial conversation ends the same way: “If not for 280E, we’d be thriving.” That line gets repeated in boardrooms and investor decks across the country, and for good reason. Section 280E has choked margins, slowed growth, and kept great [...]
Global cannabis trade is well underway as legalized countries move forward to establish a supply chain infrastructure in a newly formed and rapidly evolving industry. At the forefront of transportation logistics is Cannabilog, an Israeli company led by pharmaceutical industry veteran Yoram Eshel. In an interview, [...]
Experts say real-world evidence could offer crucial insights into how these medicines work in practice, and help widen access for patients. For the last 50 years, randomised controlled trials (RCTs) have been considered the ‘gold standard’ research methodology for measuring the safety and efficacy of new [...]
In a historic move, Spain’s Council of Ministers has approved a long-awaited Royal Decree regulating the medicinal use of cannabis preparations in hospital settings. Following years of advocacy on behalf of patients and campaigners, the decision marks a decisive step toward the integration of medical cannabis [...]
As our bodies age, the mechanisms that keep our systems humming, such as immune regulation, metabolism, and neural repair, gradually erode. That loss of homeostasis is the culprit behind many age-related disorders, from cognitive decline to metabolic dysfunction. Scientists are beginning to explore whether cannabis or [...]
Germany’s booming cannabis market, which Prohibition Partners now estimates to be worth around €670m, is entering uncertain and potentially treacherous territory. As the landmark CanG Act approaches its second year, it has become a highly charged and increasingly divisive issue politically, culturally, and medically. With the [...]
Q&A with Brendan McGee, Founder, Silver Therapeutics Tell us about your product(s). What do you make or sell, and what should people know about it? At Silver Therapeutics, we’re driven to curate experiences that meet people where they are. From flower to prerolls to vapes, we [...]
Alibi Cannabis website. Q&A Tell us about your product(s). What do you make or sell, and what should people know about it? Our roots are in cultivation, so everything starts with high-quality flowers. In Oregon, our flower has won multiple awards, and we bring that focus [...]
Website: rosareta.com Tell us about your product(s). What do you make or sell, and what should people know about it? Rosa Reta crafts solventless cannabis Live Rosin vapes (All-In-One), Bubble Hash Infused prerolls, and Rosin infused gummies. We focus on clean processing, full-spectrum flavor, and consistent quality [...]
The cannabis industry’s fragmented foundation is creating a host of problems tied to the lack of federal legalization. Many experts believe that without a national medical cannabis framework, the future of cannabis as a medicine in America could leave patients unprotected, research underfunded, and the industry [...]
At PatientsCann UK, we represent the voices of patients who rely on safe, effective, and regulated access to medical cannabis. Since its legalisation in 2018, many people have continued to face unnecessary barriers to treatment, from stigma and misinformation to the limited availability of NHS prescriptions. For thousands of patients, private prescriptions remain the only viable route to accessing the medicine they need. That’s why the Department of Health and Social Care’s “Private (non-NHS) Prescribing: Call for Evidence” is such an important opportunity. This review could influence how private prescribing works in the UK, including how cannabis-based medicines are accessed, regulated, and supported by clinicians. Why This Matters The call for evidence invites responses from across the healthcare system, including clinicians, prescribers, pharmacists, healthcare organisations, and patient groups. While the questions are primarily aimed at professionals, it is crucial that patients and carers also share their experiences. By contributing evidence and lived experience, we can help policymakers understand: How private prescribing supports patients who are unable to access NHS treatment. The challenges of affordability, continuity of care, and stigma in private medical cannabis access. The need for greater clinical education and confidence around prescribing cannabis-based medicines. The importance of protecting safe, regulated, and equitable access for all patients. Our Position PatientsCann UK believes that this review must:Protect the right of patients to access regulated medical cannabis safely and affordably.Promote fairness and consistency between NHS and private prescribing pathways.Address stigma and empower clinicians to prescribe based on evidence, not fear.Encourage more research, education, and evidence-based practice across the medical field. This consultation provides a rare chance to shape how the UK approaches private prescribing, and to ensure medical cannabis patients are not overlooked. How to Take Part Your experience is evidence — share it.The Private (non-NHS) Prescribing: Call for Evidence is now open to submissions from individuals and organisations with knowledge or experience of private prescribing. Visit: Private (non-NHS) Prescribing: Call for Evidence – GOV.UKDeadline: 11:59 pm, 4 November 2025 You do not need to answer every question, but you must select Submit at the end for your response to count. How Patients Can Encourage Healthcare Professionals You can play an important role in raising awareness of this consultation within your own care networks. Here are a few ways to help: Start the conversation. Mention the review to your prescribing clinician, pharmacist, or nurse and let them know the deadline. Many professionals may not yet be aware of it. Share the link. Send your clinic, GP practice, or specialist the official GOV.UK consultation page and encourage them to share it with colleagues. Speak to both sides. Whether your care is through a private medical cannabis clinic or the NHS, professionals across both systems can contribute valuable insight on access, patient safety, and clinical challenges. Explain why it matters. Let them know that evidence from healthcare professionals — especially those working with medical cannabis — can directly shape how government policy supports safer and fairer access for patients. Spread awareness. Share our post and tag your clinic, pharmacy, or medical organisation on social media to encourage wider participation. Your voice can help ensure that both patients and healthcare professionals are represented in this important review. Important Note This consultation is separate from the ACMD call for evidence on cannabis-based medicinal products, which focuses on clinical data and scheduling. Both reviews are crucial, and we encourage responses to each. Together, we can ensure that clinicians, patients, and organisations play a leading role in shaping an equitable and evidence-based future for medical cannabis access in the UK. 💚
The post Help Shape The Future of Medical Cannabis first appeared on PatientsCann UK.
The cannabis industry is a fertile ground for aspiring entrepreneurs, holding the promise of a modern-day gold rush. Yet beneath the surface of opportunity lies a minefield of obstacles. Success requires navigating a steep learning curve, managing high operational costs, and mastering a complex supply chain [...]
Dr Sue Clenton, Medical Director of Releaf cannabis clinic explains what it takes to go from a few hundred to thousands of patients, without compromising on the quality of care. When people talk about growth in healthcare, the conversation often centres on numbers – the number [...]
New guidelines around THC levels, dosages, and eligibility, aim to bring more clarity and consistency to the practice of prescribing cannabis-based medicines in the UK. Almost seven years since medical cannabis was legalised in the UK, around 180 specialist consultants are now actively prescribing. But almost [...]
The Advisory Council on the Misuse of Drugs (ACMD) is reviewing cannabis-based products for medicinal use (CBPMs).
The post PatientsCann UK Statement on the ACMD Review of Medical Cannabis first appeared on PatientsCann UK.
Words by Lawrence Purkiss and Sarah Sinclair Portugal hosted its seventh international conference on medical cannabis (PTMC) in central Lisbon last week, amid a growing feeling that the country – a once-thriving hub for European cannabis exports – is at an inflection point. Discussion among speakers [...]
Beyond its wellness benefits, cannabis carries a rich and diverse cultural legacy that spans the globe. In a technical paper submitted to Mondiacult 2025, the Cannabis Embassy calls for global recognition of cannabis cultures as an integral part of humanity’s cultural diversity, and as essential to [...]
On April 1, 2024, Germany launched Pillar 1 of its adult-use legalization framework, building on its established medical cannabis program that has been in place since 2017. Since then, the number of medical patients has surged, as prescriptions remain the only fully legal access point for [...]
The next evolution of marketing in the cannabis industry has arrived. Global Compliance Application Corp. (GCAC), a publicly traded Canadian company specializing in blockchain technology, has launched Citizen Green, a connected TV (CTV) channel designed to educate viewers on various aspects of the cannabis industry. The [...]
By Rupa Shah, Head of Compliance at Releaf The conversation around workers’ rights and medical cannabis is still at a very early stage in the UK. Despite the fact that thousands of patients now access cannabis-based medicines legally through prescription, the framework remains poorly understood by [...]
Over the course of three years, across 13 regulated U.S. markets, BayMedica, a company specializing in the production and distribution of rare cannabinoids, identified three key insights into market demand for these compounds. First, products featuring THCV posted a 23.7% higher average retail margin than comparable [...]
Mental health advocate and one half of music duo Rizzle Kicks, Jordan Stephens, is collaborating with medical cannabis clinic, Alternaleaf, to shed light on the role of alternative treatments in supporting mental wellbeing. Stephens, who is currently touring with Rizzle Kicks as part of their comeback [...]
The UK’s medical cannabis industry is now the second largest in Europe, second only to Germany, thanks to consistent and sustained growth over the last seven years. While this has seen thousands of new patients gain access to medical cannabis, it still represents just a fraction [...]
A Yorkshire man, who supplied cannabis products to thousands of people with chronic illnesses, has been jailed for four years after his original suspended sentence was overturned. Joel Cunningham, 40, from Leeds, was convicted of seven offences, including possession with intent to supply magic mushrooms and [...]
Red Light Holland (CSE: TRIP) has established its foundation in the Netherlands, where psilocybin truffles, the underground sclerotia of psilocybin mushrooms, are legally permitted for cultivation and sale. The above-ground mushroom is prohibited, but the truffle is treated differently under Dutch law, despite delivering the same [...]
MJBizCon, the largest and one of the most influential gatherings in the cannabis industry, is adding a new element to its lineup: a cannabis competition. This year marks the debut of the MJBowl awards on December 4th in Las Vegas, produced in partnership with Budist, the [...]
In an industry defined by local operators struggling to stay afloat and confined within their borders, Michael Sassano, founder and CEO of Somai Pharmaceuticals, has created a blueprint for scaling cannabis worldwide with pharmaceutical discipline and regulatory agility. With headquarters in Lisbon and operations in [...]
Whether it’s a single retail license, a multi-site operation, or a vertically integrated enterprise, deals in Arizona are fetching top-tier premiums – often exceeding price points in larger, more mature markets like California. So, what’s driving these sky-high valuations? More importantly, how can industry players take [...]
Cannabis Health has partnered with leading experts at the Medical Cannabis Clinicians Society (MCCS) to bring its first educational event for healthcare professionals to the UK later this year. The Cannabis Health Symposium, taking place at Conway Hall in London on 25 November, 2025, will welcome [...]
New analysis has found that NHS access to medical cannabis could boost the UK’s economy by £13.3 billion over the next decade by returning thousands back to work. Widening NHS access to medical cannabis could add £4.5 billion to the economy over five years, and £13.3 [...]
Switching from smoking to dry-herb vaping offers a safer way to consume while also preserving the delicate terpene and cannabinoid profiles that contribute to the entourage effect. Unlike combustion, which produces tar, carbon monoxide, and other toxic byproducts, vaporization heats cannabis at controlled temperatures to release [...]
A major new study, analysing data from over four million adults in the US and Europe, has linked cannabis use to an almost quadrupling in the risk of developing type 2 diabetes. Cannabis use is increasing globally with an estimated 219 million users (4.3% of the [...]
The excitement and interest around New Jersey are impossible to ignore because of its potential to be one of the most lucrative cannabis markets in the country. Since legalization, operators have been racing to open doors, capture consumers, and keep pace with evolving regulations, as they [...]
The age of cannabis receiverships is here. If you’re a creditor, operator, landlord, or investor in a troubled cannabis business, you have a choice: watch value evaporate, or step up and run a disciplined, court-supervised sale that maximizes recoveries and preserves the company as a going [...]
Two new studies, one a large meta-analysis and the other real-world evidence from the UK, suggest that cannabis-based medicines, particularly those containing THC or mixed cannabinoids, may improve sleep quality and ease symptoms of insomnia. A new systematic review and meta-analysis, published in the journal Sleep [...]
The UK’s long-running project to regulate CBD (cannabidiol) products has taken another major step forward, seeing thousands of products make it to the final phase of the novel foods approval process. Yesterday, the Food Standards Agency (FSA) announced that its 12-week public consultation to discuss the [...]
Curaleaf Laboratories, part of Curaleaf International, today announced the UK launch of the Curaleaf Que Medical Inhalation Device (QMID), the first CE-certified liquid inhaler for cannabis-based medicines. Available on prescription, the device offers patients a precise, discreet, and clinically approved way to inhale cannabis-based treatments. Since [...]
Cannabis Health will host its first expert-led educational event for healthcare professionals later this year, with a focus on bridging the gap between policy and patient access. The one-day, CPD-accredited Cannabis Health Symposium, taking place at Conway Hall in London on Tuesday 25 November, 2025, is [...]
Despite a slow start in facilitating patient access to medical cannabis treatments, this is gradually changing for the better. The UK now has an active patient base of approximately 50,000-60,000, and an estimated 80,000 individuals are expected to receive treatment with CBPMs throughout 2025. The CQC [...]
Scientists in South Africa say they have found the first evidence of a rare class of phenolics, called ‘flavoalkaloids’, in leaves from the cannabis plant. Phenolic compounds, especially flavonoids, are well-known and sought after in the pharmaceutical industry because of their antioxidant, anti-inflammatory, and anti-carcinogenic properties. [...]
A new review has found ‘consistent evidence’ that cannabis improves sexual function in women, and should be considered as a first-line treatment for patients with female orgasm disorder (FOD). After reviewing findings from 16 peer-reviewed studies, including data from over 8,000 women, researchers have formally recommended [...]
A UK medical cannabis clinic is carrying out investigations after a substantial amount of patients’ information was leaked in a major data breach. In an email sent to patients on Monday 18 August, CB1 Medical confirmed it had identified a ‘data security incident’ when patients’ personal [...]
PatientsCann UK has raised urgent concerns with both the UK and Republic of Ireland (ROI) governments over the risks faced by patients prescribed medicines that are classified as Schedule 1 Controlled Drugs in one jurisdiction but legally prescribed in the other. At present, a prescription issued in the UK, ROI or Crown Dependencies cannot be dispensed across the border if the medicine is considered Schedule 1. More critically, patients cannot lawfully carry these prescribed medicines across the border, even if the crossing is unavoidable in order to travel within their own country. This issue disproportionately affects border communities, where travel across the border is not optional but a daily necessity. For patients in these communities, this creates an impossible situation: return home with their prescribed treatment and risk criminalisation, or forego essential medication. Couriers and healthcare professionals delivering medicines face the same challenge. Practical problems and risks The current situation gives rise to multiple, connected harms: Beyond individual harm, the problem creates wider public-health and administrative issues: increased emergency presentations, greater strain on social care and inequitable access to treatment depending on postcode. What PatientsCann UK is asking for PatientsCann UK has written to the governments of the UK and the Republic of Ireland requesting urgent clarification and guidance, including: The Northern Ireland Office has confirmed that officials are reviewing our letter. PatientsCann UK welcomes this development and will continue to press for clear, rapid action to protect patients who rely on any prescribed medicine. Sal Aziz, Director of PatientsCann UK, said: “Patients should never have to choose between taking their prescribed medicine and risking criminalisation. In practice this is what border communities on the island of Ireland face today. Governments must issue clear operational guidance and protections, urgently, so patients can continue to receive care without fear.” What happens next PatientsCann UK will publish updates as official responses are received. In the meantime, anyone affected by this issue is encouraged to contact PatientsCann UK so we can collate evidence and ensure our representations fully reflect the scale and immediacy of the problem. Please email info@patientscann.org.uk or send us a message on socials (Instagram | X).
The post Border Patients at Risk: PatientsCann Raises Concerns with UK & Ireland first appeared on PatientsCann UK.
A new survey of NHS doctors has highlighted a growing demand for alternative treatment options for complex health issues such as chronic pain and women’s health-related concerns. Out of 500 doctors currently practicing in the NHS, almost half of which were GPs, three quarters said that [...]
Ireland has become the latest jurisdiction to ban the use of the semi-synthetic cannabinoid HHC, with ministers raising concerns related to growing use among young people and risks to mental health. The decision, announced by the Department of Health on 29 July, sees Hexahydrocannabinol (HHC) classified as [...]
New research on a large data set of older adults suggests cannabis use may be linked to slower brain ageing and improved cognitive function. The study, which used data collected from 25,000 adults aged between 44 and 81 years, found that those who had consumed cannabis [...]
A new study is the first to confirm a link between an invasive fungal infection and a medical cannabis product sold to a patient in the US. A cancer patient, using medical cannabis to manage the side effects of chemotherapy, developed a life-threatening fungal infection after [...]
Just months ago, France’s long battle to establish a permanent generalised medical cannabis framework was on the brink of failure. Despite other major European countries looking to France’s 2019 pilot scheme for inspiration, COVID-19, waning political will, operational hurdles, and the dissolution of the National Assembly [...]
A recent study by researchers at the University of California San Diego School of Medicine has found that individuals with cannabis use disorder (CUD) are more than three times more likely to develop oral cancer within five years compared to those without CUD. In 2022, 17.7 [...]
The Care Quality Commission has raised a number of concerns related to the prescribing of cannabis-based products for medicinal use in the UK, as the latest data reveals further increases in private prescriptions. Earlier this month the independent regulator which is responsible for overseeing health and [...]
Copyright © 2020 – 2026 | The Cannabis Pages | All Rights Reserved | Important Notice | The Cannabis Pages “TCP” is an information resource for medical cannabis patients and prescribers. Nothing on the site should be construed as a promotion or inducement. TCP does not promote any product or represent that the products mentioned on TCP’s website are treatment for any kind of medical condition. TCP cannot guarantee that information provided is error-free or complete and is not responsible for the quality of the information provided by users. Cannabis is an unlicensed medication which can only be administered under the supervision of a licensed physician.
